Our novel findings regarding the EGF/PI3K/AKT/MKRN1 axis leading to PTEN suppression, along with previous data on mutations in ERBB2, and PIK3CA, ultimately indicate that ERBB2- or PIK3CA-targeted drugs might be potential therapeutic treatments for cervical cancers. The gene discussed is EGF; the disease is cervical cancer.